PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 850
- Registration Number
- NCT06531109
- Locations
- πΊπΈ
C2 Research Center, Montgomery, Alabama, United States
πΊπΈRao Dermatology, Fresno, California, United States
πΊπΈSouthern California Clinical Research, Santa Ana, California, United States
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
Phase 2
Recruiting
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)Biological: 15-valent pneumococcal conjugate vaccine (PCV15)
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 800
- Registration Number
- NCT06524414
- Locations
- π΅π·
Caribbean Medical Research Center, San Juan, Puerto Rico
π΅π·University of Puerto Rico - Medical Sciences Campus, San Juan, Puerto Rico
π΅π·The Hispanic Alliance for Clinical and Translational Research, San Juan, Puerto Rico
A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT06507904
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2
- Registration Number
- NCT06504524
- Locations
- π©πͺ
Pfizer, Berlin, Germany
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Active, not recruiting
- Conditions
- Breast CancerMalignant Neoplasm of Breast
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5087
- Registration Number
- NCT06495164
- Locations
- πΊπΈ
Pfizer New York, New York, New York, United States
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT06487078
- Locations
- π«π·
Institut Godinot, Reims Cedex, France
SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTS
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 490
- Registration Number
- NCT06482099
- Locations
- π―π΅
Pfizer, Tokyo, Japan
Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.
Active, not recruiting
- Conditions
- Relapsed and Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT06479954
- Locations
- π―π΅
Pfizer, Tokyo, Japan
A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia.
Active, not recruiting
- Conditions
- Acute Lymphocytic Leukemia
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT06476665
- Locations
- π―π΅
Pfizer, Tokyo, Japan
A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults.
Phase 3
Completed
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Biological: RSVpreF MDVBiological: RSVpreF SDV
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 452
- Registration Number
- NCT06473519
- Locations
- πΊπΈ
Clinical Research Prime, Idaho Falls, Idaho, United States
πΊπΈHeadlands Research - Detroit, Southfield, Michigan, United States
πΊπΈClinical Trials of Texas, LLC dba Flourish Research, San Antonio, Texas, United States
Β© Copyright 2025. All Rights Reserved by MedPath